3D Imaging Market Growth Size, Opportunities, Future Scope, Business Scenario, Share, Key Segments And Forecast To 2028
"GE Healthcare (US), Autodesk (US), STMicroelectronics (Switzerland), Panasonic (Japan), Sony Corporation (Japan), Trimble (US), FARO Technologies (US), Philips (Netherlands), Google (US), Adobe (US), HP (US), Dassault Systemes (France), Bentley Systems (US), Lockheed Martin (US), Topcon (Japan), Able Software (US), Maxon (Germany)."
3D Imaging Market by Hardware (3D Cameras, 3D Sensors, 3D Scanners), Software (Modeling, Scanning, Layout & Animation, Visualization & Rendering, Image Reconstruction), Technology (Stereoscopic Imaging, Laser-based Imaging) - Global Forecast to 2028.
The global 3D imaging market is expected to expand at a compound annual growth rate (CAGR) of 20.8% from USD 34.3 billion in 2023 to USD 88.4 billion by 2028. On flat surfaces, 3D imaging creates depth-perceptive three-dimensional images that replicate depth perception in the actual world. This technology is widely used in many different industry verticals, including as manufacturing, healthcare and life sciences, automotive, retail and e-commerce, aerospace and defense, and others. In order to simulate depth perception, technologies like stereoscopy use two camera lenses that are slightly separated to capture 3D images on 2D planes. This wide range of techniques highlights how 3D imaging revolutionizes the way that digital content is perceived and affects graphics across industries.
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=998
Automotive sector to hold the largest market size during the forecast period.
3D imaging in the automotive sector revolutionizes safety systems such as LiDAR for ADAS and self-driving cars, enabling detailed environment mapping and object recognition. Beyond safety, it optimizes maintenance and repairs by providing accurate diagnostics. Additionally, it enhances customer experiences through immersive interactions, allowing virtual exploration of vehicles. By elevating safety measures, improving maintenance efficiency, and offering engaging customer interactions, 3D imaging reshapes the automotive landscape toward safer, more efficient, and consumer-centric advancements.
Services Segment to hold the highest CAGR during the forecast period.
The surging demand for real-time 3D solutions across diverse industries drives the emergence of 3D services tailored for medical imaging, scanning, architectural design, and animation in movies. These services are integral, offering product upgrades, maintenance, training, and consulting, vital in leveraging 3D imaging effectively. It expedite the creation, assessment, and utilization of 3D models, saving time and effort compared to traditional imaging methods. Incorporating managed and professional services further enhances 3D imaging solutions, streamlining processes and maximizing the efficiency of diverse applications within this dynamic technological landscape.
Asia Pacific to exhibit the highest CAGR during the forecast period.
The Asia Pacific region showcases robust and progressive adoption of new technologies, poised to achieve the highest CAGR in the forecasted period. The proliferation of high-end machinery across diverse industries propels the demand for 3D imaging hardware, software, and services. Key countries such as China, India, Japan, and other Asia Pacific countries contribute significantly to advancing 3D displays and image sensors. Verticals such as healthcare, manufacturing, automotive, retail, media, and architecture are embracing cloud adoption vigorously in Asia Pacific. The region's cost efficiency fuels manufacturing, making it a hub for companies, this drives the demand for 3D sensors, pivotal for monitoring and inspecting components in manufacturing processes.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=998
Unique Features in the 3D Imaging Market
The 3D imaging market is defined by its use of advanced technologies like structured light, laser scanning, stereoscopic vision, and time-of-flight (ToF) sensors. These technologies enable accurate depth perception and spatial recognition, which are critical for applications in sectors such as healthcare, automotive, and entertainment.
A standout feature in modern 3D imaging is the ability to render and process images in real time. This is especially vital in applications like augmented reality (AR), virtual reality (VR), and robotics, where dynamic environmental data needs to be captured and interpreted instantly.
The integration of artificial intelligence (AI) and machine learning (ML) enhances 3D imaging systems by allowing automated recognition, classification, and analysis of 3D data. This has led to improvements in medical diagnostics, facial recognition, and industrial quality control.
3D imaging systems are increasingly offering micron-level precision, which is essential in applications such as surgical planning, prosthetics design, and aerospace component inspection. This level of accuracy surpasses that of traditional 2D imaging.
Major Highlights of the 3D Imaging Market
The 3D imaging market has seen substantial growth in recent years, driven by increasing demand across industries such as healthcare, automotive, aerospace, entertainment, and manufacturing. Factors such as technological advancements, growing adoption of automation, and the proliferation of digital content have contributed significantly to this market expansion.
3D imaging is no longer confined to traditional sectors. It is now extensively used in areas like medical diagnostics (MRI, CT scans), industrial inspection, urban planning, gaming, and virtual prototyping. Its ability to provide accurate visual representations makes it a valuable tool across both consumer and enterprise segments.
Innovations in sensor technology, artificial intelligence, computer vision, and 5G connectivity are driving the capabilities of 3D imaging systems. These advancements are enabling higher resolution, faster processing speeds, and more compact devices, which make the technology more accessible and efficient.
The surge in demand for augmented reality (AR) and virtual reality (VR) experiences in gaming, retail, training, and remote collaboration is a major driver. 3D imaging forms the backbone of immersive content creation, enabling realistic simulations and environments that enhance user interaction and engagement.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=998
Top Companies in the 3D Imaging Market
Major vendors in the global 3D Imaging market are GE Healthcare (US), Autodesk (US), STMicroelectronics (Switzerland), Panasonic (Japan), Sony Corporation (Japan), Trimble (US), FARO Technologies (US), Philips (Netherlands), Google (US), Adobe (US), HP (US), Dassault Systemes (France), Bentley Systems (US), Lockheed Martin (US), Topcon (Japan), Able Software (US), Maxon (Germany), ESRI (US), Archilogic (Switzerland), Pix4D (Switzerland), Brainkey (US), Precismo (US), Kaarta (US), LightCode Photonics (Estonia), Vzense Technology (US), Capoom (Istanbul), Atomontage (US), Hivemapper (US), Shapr3D (Hungary), Innersight (UK).
GE Healthcare, a division of GE (NYSE: GE), holds a prominent position in the healthcare sector, offering a diverse range of medical technology, pharmaceutical diagnostics, and digital solutions. Its Edison intelligence platform and smart devices empower healthcare professionals to make swift, well-informed decisions, integrating data analytics and applications. With a legacy spanning over a century and a global workforce of around 48,000 employees, GE Healthcare operates at the core of a collaborative healthcare ecosystem. Its primary focus revolves around advancing precision health by digitizing healthcare processes, fostering productivity, and enhancing patient and provider outcomes worldwide.
The company's dedication to innovation and leading-edge technology cements their role as pioneers in driving healthcare transformation. Its holistic approach, merging technology, data analytics, and services, aligns seamlessly with the dynamic needs of the healthcare domain. Through fostering collaboration and drawing upon their extensive expertise, GE Healthcare continues to significantly impact healthcare delivery and patient care on a global scale.
Autodesk is revolutionizing global design and production across multiple industries such as architecture, construction, manufacturing, media, and entertainment. Its comprehensive suite of software, including AutoCAD, Revit, Maya, 3ds Max, Fusion 360, SketchBook, and more, is utilized by over 100 million users worldwide. These tools serve as catalysts for unlocking creativity while addressing crucial design, business, and environmental challenges. Accessible on both personal computers and mobile devices, Autodesk software harnesses the infinite computational capabilities offered by the cloud. This enables seamless collaboration and the realization of intricate 3D concepts for teams across the globe. From enabling the creation of environmentally sustainable buildings to revolutionizing product innovation and contributing to visually stunning entertainment, our tools play a pivotal role in shaping a better world.
Trimble is a technology leader, offering transformative solutions that redefine how industries measure, build, evolve, and transport goods, ultimately enhancing the quality of life. Through pivotal technologies such as positioning, modeling, connectivity, and data analytics, Trimble serves as a bridge between the digital and physical worlds. This integration aims to elevate productivity, enhance quality, ensure safety, increase transparency, and promote sustainability across various sectors.
Trimble's diverse portfolio, ranging from purpose-built products to comprehensive enterprise solutions and industry-specific cloud services, holds the power to revolutionize critical industries such as construction, geospatial mapping, agriculture, and transportation. By infusing innovation into these sectors, Trimble enables an interconnected ecosystem, fostering a world where work thrives on seamless connectivity, efficiency, and adaptability. Its vision and commitment to leveraging technology for the betterment of industries and society drive their efforts to create an interconnected global landscape where progress and efficiency go hand in hand.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
43 minutes ago
- Globe and Mail
The $12.6 Billion Quantum Leap: High-Potential Stocks Under $10 (ZENA, SKYT, LAES, BTQQF)
Quantum computing is emerging as one of the most promising frontiers in technology today. Unlike traditional computers that use bits as the smallest unit of data, quantum computers use quantum bits or qubits, which can exist in multiple states simultaneously. This allows quantum systems to tackle complex problems far beyond the capabilities of classical computers, solving them faster and more efficiently. While often overshadowed by the hype around artificial intelligence, quantum computing is steadily gaining traction. It is driving breakthroughs in areas such as machine learning, image and speech recognition, and optimization problems. The technology's potential is attracting significant investor attention, with some betting it could spark growth on par with the AI revolution. The market for quantum computing is expanding rapidly. According to Fortune Business Insights, the global quantum computing market was valued at $885 million in 2023 and is expected to soar to over $12.6 billion by 2032, growing at an annual rate of nearly 35 percent. This rapid growth highlights the sector's rising importance and opportunity. Within this dynamic landscape, smaller high-tech companies trading under $10 often have the potential to become breakout performers. They offer investors a chance to get in early on the next wave of innovation without the high price tag of established giants. Now, let us explore some of the promising rising stocks in this fast-growing quantum computing sector. Among the most compelling under-the-radar quantum computing stocks under $10, ZenaTech (Nasdaq: ZENA) stands out with its rare blend of AI drone technology, Drone as a Service (DaaS), enterprise software, and quantum innovation. The company reported an impressive 92 percent year-over-year revenue growth in the first quarter of 2025, climbing to $1.13 million from $591,379 in Q1 2024. This surge was driven by organic momentum and key acquisitions in drone services and enterprise software, showcasing a firm that is not only scaling but strategically positioning itself in rapidly expanding markets. ZenaTech operates through its drone-focused subsidiary ZenaDrone and a growing network of global offices in North America, Europe, Taiwan, and the UAE. It develops autonomous AI-powered drones capable of integrating machine learning, predictive modeling, and now, quantum computing. These drones are already in field use across agriculture, logistics, defense, and surveillance applications. But the company's most ambitious and potentially disruptive initiative is its Clear Sky project, which combines AI drone swarms with quantum computing to transform how we predict and respond to extreme weather events. The Clear Sky project aims to address a growing global challenge. In 2024 alone, there were 58 separate billion-dollar weather disasters, including 27 in the United States. These included hurricanes, floods, wildfires, and storms that caused $417 billion in global losses, according to Gallagher Re. ZenaTech's solution uses coordinated drone fleets outfitted with advanced sensors to collect real-time atmospheric data across different layers of the sky. The data is then processed using quantum computing systems that can handle massive, complex datasets at unprecedented speed and resolution. 'Drones with sensors flying at high altitudes can collect data in real time, enabling greater spatial and temporal resolution,' said CEO Shaun Passley, Ph.D. 'This results in more precise, up-to-the-minute weather insights to better anticipate the onset of extreme weather like tornadoes.' AI drone swarms enhance the frequency and localization of measurements, delivering a leap forward in meteorological forecasting capabilities and early disaster warnings. In addition to weather forecasting, ZenaTech is now using this same AI-quantum fusion to address wildfire threats in the US West. The company's drones, equipped with thermal and multispectral sensors and 360-degree LiDAR, are deployed across hundreds of square miles to simulate wildfire spread and optimize emergency responses. A newly acquired land surveying firm in Oregon and partnerships with Native American communities in Wyoming support this initiative, enhancing field data collection and real-world testing environments. The first quarter also marked major product milestones, including the third-generation ZenaDrone 1000 entering scalable production, and the IQ Square drone moving to manufacturing. ZenaTech began work on a heavy-lift, gas-powered ZD 1000 variant for US defense applications and initiated testing of a high-density drone battery and proprietary communications system. The company also ramped up hiring, bringing on 35 new engineers and technicians to expand drone development in the UAE and opened a new drone testing facility in Turkey. ZenaTech's enterprise software business is also advancing, highlighted by its acquisition of Othership, a UK-based workplace management platform. This complements its SaaS offerings and introduces AI and quantum productivity tools aimed at government and business clients. While expenses rose in the first quarter due to rapid expansion, hiring, and R&D investment, the long-term strategy is clear. ZenaTech is building a platform company with national and international scale across drone hardware, software, and quantum-driven analytics. The company is preparing for Green and Blue UAS certification, a necessary step to access US military contracts, and is developing secure, certifiable drone sensors in Taiwan. ZenaTech (Nasdaq: ZENA) is a rare sub-$10 stock with exposure to multiple exponential technologies. With nearly doubled revenues, expanding drone deployments, growing defense ties, and pioneering work in quantum-enhanced weather and wildfire response, the company offers high-upside potential in one of the most dynamic corners of the tech market. SkyWater Technology (NASDAQ: SKYT) is emerging as a pivotal player in the push to restore and expand secure U.S. semiconductor manufacturing. With shares still trading under ten dollars, the company has quietly built serious momentum on multiple fronts, including next-generation quantum breakthroughs, boardroom reinforcements, and a major upcoming acquisition that could reshape its production capabilities. One of SKYT's biggest catalysts came in March when partner D-Wave Quantum published peer-reviewed research in Science validating quantum supremacy in simulation. The research used superconducting qubits fabricated by SkyWater, and the prototype processor outperformed one of the most powerful classical supercomputers in modeling magnetic materials. This milestone underscored SkyWater's role in enabling a major leap in quantum computing. CEO Thomas Sonderman called it 'an unprecedented innovation' and emphasized the importance of expanding foundational node infrastructure in the United States. The partnership between D-Wave and SKYT spans more than a decade, and SkyWater's advanced capabilities in custom material deposition and large-scale fabrication were essential to commercializing the breakthrough. Leadership changes are also adding weight to the bull case for SKYT. In April, the company added three seasoned executives to its board, including Timothy Baxter, former CEO of Samsung North America, who is set to become board chair. Baxter brings deep strategic experience in emerging technologies like AI, 5G, and cloud infrastructure. He is joined by Tammy Miller, a former lieutenant governor and longtime CEO of Border States Electric, and Andrew LaFrence, a former KPMG partner and CFO with life sciences and government manufacturing experience. According to Sonderman, these additions strengthen the company's ability to accelerate its expansion strategy and navigate a fast-changing landscape. SkyWater also appointed Dr. Percy Gilbert as senior vice president of engineering. With a technical background that includes IBM, NXP, and Motorola, Gilbert will play a key role in scaling operations and supporting SKYT's growth in wafer services and advanced technology. Notably, he steps in as the company prepares to close its acquisition of Infineon's Fab 25 facility in Austin. Backed by a supply agreement valued above one billion dollars, this deal could prove transformational. Management believes Fab 25 is uniquely positioned to provide the scale and process flexibility needed to meet foundational semiconductor demand, while aligning tightly with national supply chain security goals. Financially, SkyWater (NASDAQ: SKYT) reported strong sequential growth in wafer services during the first quarter of 2025, driven by adoption of its new ThermaView platform among defense contractors. While budget delays in Washington have temporarily softened the outlook for advanced technology services, management remains confident in year-over-year revenue growth for both business segments and expects to deliver strong adjusted EBITDA and positive non-GAAP EPS for the full year. With the Infineon deal expected to close by mid-year and a ramp in advanced packaging revenues coming in the second half, SkyWater looks well-positioned to unlock meaningful long-term upside. SEALSQ Corp (NASDAQ: LAES) stands out in the post-quantum technology space by developing advanced hardware and software solutions that safeguard against the emerging threat of quantum computing. Their products combine semiconductors, public key infrastructure (PKI), and provisioning services, emphasizing the highest-level quantum-resistant cryptography designed to replace vulnerable traditional encryption methods like RSA and ECC. In May 2025, SEALSQ announced that its flagship QVault Trusted Platform Module (TPM) achieved compliance with ML-DSA-87 and ML-KEM-1024 — the most secure NIST-standardized algorithms (CRYSTALS-Dilithium and CRYSTALS-Kyber) currently available for post-quantum cryptography. These algorithms provide AES-256 equivalent security and are tailored for defense, IoT, and automotive markets that demand the strongest protection for firmware signing, secure communications, and device authentication. The QVault TPM offers a tamper-resistant environment to shield cryptographic keys and operations, certified to stringent standards like FIPS 140-2/3 and Common Criteria EAL5+. Beyond hardware, LAES is pushing boundaries with its space-based quantum initiatives. The company is set to lead the world's first space-based Quantum Key Distribution (QKD) proof-of-concept through the June 2025 launch of WISeSat 2.1. This mission embeds SEALSQ's Quantum RootKey technology into a satellite, paving the way for ultra-secure, sovereign quantum-resistant satellite communications. The WISeSat constellation, backed by a $10 million SEALSQ investment, promises to extend quantum-safe communications and decentralized IoT transactions globally, including remote areas where traditional networks struggle. SEALSQ is also expanding its impact in consumer IoT. Recently, global smart home leader Hager selected SEALSQ's PKI-as-a-Service platform, INeS, to provide device attestation certificates for its Matter-compliant smart home products. INeS delivers post-quantum secure certificates, ensuring long-term protection for billions of connected devices in the smart home ecosystem. With rising cyber threats and the quantum computing horizon looming, SEALSQ's integrated approach across semiconductors, satellite communications, and IoT security positions it as a key player in the next generation of unbreakable digital trust. BTQ Technologies Corp. (OTCQX: BTQQF) is emerging as a serious contender among the rising quantum stocks under $10. Founded by a team of post-quantum cryptographers, the company is building a platform that bridges cryptographic software with purpose-built hardware to defend against the future threats of large-scale universal quantum computers. Recent developments highlight BTQ's commitment to both technical innovation and global engagement. In April, BTQQF signed a Memorandum of Understanding with EntangleTech, a leading quantum education organization in Taiwan. The partnership will support the creation of educational content focused on quantum computing and emerging technologies. BTQ is contributing both funding and expertise, helping EntangleTech produce accessible materials such as videos and podcasts designed to boost quantum literacy. This move underscores BTQ's commitment to public education and international collaboration, positioning the company as a global voice in the quantum space. Shortly after, BTQ announced another MOU with Quandela, a photonic quantum computing company based in France. Together, they will test BTQ's Quantum Sampling Proof-of-Work protocol, a quantum-secure and energy-efficient alternative to traditional blockchain mining. If successful, this collaboration could lay the foundation for a more sustainable and quantum-resilient blockchain future. It also opens the door for commercial applications of Quandela's Belenos quantum processor within BTQ's protocol. More recently, BTQ signed an agreement with ICTK, a South Korean semiconductor security firm known for its PUF-based chip technologies. This partnership will explore the joint development of secure cold wallets and other hardware solutions using BTQ's proprietary CASH architecture. The system is capable of processing up to one million digital signatures per second and encrypting data up to five times faster than competing solutions. Compact, energy-efficient, and quantum-ready, CASH is designed to protect vital systems in finance, telecom, identity, and embedded devices. BTQ Technologies Corp. is not only advancing the science of post-quantum cryptography but also securing partnerships and infrastructure that could give it a real edge in the quantum transition. For investors seeking long-term exposure to quantum resilience and security innovation, BTQ stands out as a stock to watch. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact Company Name: RazorPitch Contact Person: Mark McKelvie Email: Send Email City: NAPLES State: Florida Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
Your brain on AI
In Depth Will tools designed to help us instead atrophy our critical-thinking skills? As tech companies court students, educators calculate the long-term risks Joe Castaldo The Globe and Mail Photo illustration by The Globe and Mail to view this content.
Globe and Mail
8 hours ago
- Globe and Mail
Wet Age-Related Macular Degeneration (Wet-AMD) Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Prevalence, and Companies by DelveInsight
Wet Age-Related Macular Degeneration Companies are Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. (Albany, USA) DelveInsight's ' Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Wet Age-Related Macular Degeneration market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Wet Age-Related Macular Degeneration market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Wet Age-Related Macular Degeneration market. Key Takeaways from the Wet Age-Related Macular Degeneration Market Report In May 2025, Kodiak Sciences Inc announced results of a Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In May 2025, NexThera Co., Ltd announced results of a Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD) In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023. The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future. Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases). Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM. Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023. The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023. Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases). Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM. In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand). The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR. The leading Wet Age-Related Macular Degeneration Companies such as Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Marketed Drugs • BEOVU (Brolucizumab): Novartis BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules. • EYLEA (aflibercept): Regeneron Pharmaceuticals EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials. • VABYSMO (faricimab): Roche/ Genentech, Inc. VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels. Wet Age-Related Macular Degeneration Emerging Drugs • OPT-302: Opthea Limited OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. • KSI-501: Kodiak Sciences Inc. KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. Wet Age-Related Macular Degeneration Market Outlook Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients. The Wet Age-Related Macular Degeneration (wAMD) market is driven by several key factors, including the rising prevalence of the disease due to an aging global population, increased awareness and early diagnosis, and ongoing advancements in treatment options such as anti-VEGF therapies and emerging gene therapies. Additionally, robust research pipelines, growing healthcare expenditure, and supportive government initiatives further contribute to market growth. However, the market also faces notable barriers, such as the high cost of treatment, limited accessibility in low-income regions, the need for frequent intravitreal injections, and challenges in achieving long-term efficacy and patient adherence. Moreover, competition among therapeutic alternatives and the complex nature of drug development for retinal diseases can also hinder market expansion. Wet Age-Related Macular Degeneration Drugs Uptake The drug chapter of the Wet Age-Related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Wet Age-Related Macular Degeneration. Major Wet Age-Related Macular Degeneration Companies are Opthea Limited (ASX: OPT), Outlook Therapeutics (NASDAQ: OTLK), Kodiak Sciences (NASDAQ: KOD), Regenxbio (NASDAQ: RGNX), Dobecure (Private), Gemini Therapeutics (NASDAQ: GMTX), Huabo Biopharm (Private), Isarna Therapeutics (Private), IVERIC bio (NASDAQ: ISEE), Ribomic (TYO: 4591), Curacle (KOSDAQ: 301300), Bio-Thera Solutions (SHA: 688177), AngioLab Inc. (KOSDAQ: 251280), Alkahest (Acquired by Grifols – BME: GRF), Tyrogenex (Private), Iconic Therapeutics (Private), AiViva BioPharma (Private), Boehringer Ingelheim (Private), RemeGen (HKEX: 9995, SHA: 688331), and others Scope of the Wet Age-Related Macular Degeneration Market Report Coverage- 7MM Study Period- 2020-2034 Wet Age-Related Macular Degeneration Companies- Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment and FDA Approvals Table of Content 1 Key Insights 2 Report Introduction 3 Wet AMD Market Overview at a Glance 4 Wet AMD Market: Future Perspective 5 Executive Summary 6 Key Events 7 Disease Background and Overview 8 Epidemiology and Patient Population 9 Patient Journey 10 Marketed Drugs 11 Emerging Drugs of Wet AMD 12 Wet AMD: Market Analysis 13 Key Opinion Leaders' Views 14 SWOT Analysis 15 Unmet Needs 16 Market Access and Reimbursement 17 Appendix 18 DelveInsight Capabilities 19 Disclaimer About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
